Analytical Data
-
Gene name
Galectin-14/LGALS14
-
简介
PPL13/LGALS14 is a mammalian placenta-specific galectin with placental specificity. Many placental lectins induce apoptosis of activated T cells and other leukocytes, thereby conferring immune tolerance to the recipient. Galectin-14/LGALS14 Protein, Human (HEK293, His) is the recombinant human-derived Galectin-14/LGALS14 protein, expressed by HEK293 , with C-6*His labeled tag.
- Application
-
Alternative Names
rHuPlacental protein 13-like/LGALS14, His; Placental Protein 13-Like; Charcot-Leyden Crystal Protein 2; CLC2; Galectin-14; Gal-14; LGALS14; PPL13
-
Species
Human
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAH22257.1
-
Expression Region
M1-D139
-
Protein Length
Full Length
-
Molecular Weight
16 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Galectin-14, also known as LGALS14, is a member of the galectin family of proteins, which are beta-galactoside-binding lectins with significant roles in various biological processes, including cell adhesion, immune response, and apoptosis. Research on Galectin-14 has gained interest due to its involvement in reproductive biology and potential implications in pregnancy, such as embryo implantation and trophoblast interaction with the maternal environment. It is predominantly expressed in the female reproductive system, particularly during the early stages of gestation. The study of recombinant Galectin-14 protein is crucial for elucidating its molecular mechanisms and understanding its functional roles. By producing Galectin-14 in a recombinant form, researchers aim to investigate its binding properties, structure-function relationships, and interactions with glycosylated ligands. This can lead to insights into its potential therapeutic applications, including its role in fertility treatments and managing pregnancy-related complications. Additionally, elucidating the pathway regulated by Galectin-14 can enhance our understanding of its contribution to reproductive health and may uncover novel targets for clinical intervention. Overall, the study of recombinant LGALS14 holds promise for advancing knowledge in reproductive biology and developing therapeutic strategies for related disorders.
